

January 4, 2021

National Stock Exchange of India Limited
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra East
Mumbai – 400 051
NSE Symbol: AMARAJABAT

BSE Limited
Corporate Relations Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001
BSE SCRIIP CODE: 500008

Dear Sirs,

Sub: Disclosure under Regulation 30 and 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement regarding notice of the Board Meeting scheduled on February 13, 2021 as published in Business Line (English) and Andhra Jyothi (Telugu) newspapers on January 1, 2021.

We request you to take on record and acknowledge the same.

Thanking you,
Yours faithfully,

For Amara Raja Batteries Limited

RAJARAM
RANGANATHAN
MOSUR

Digitally signed by RAJARAM RANGANATHAN MOSUR
DN: cn=RAJARAM RANGANATHAN MOSUR, o=Amara Raja Batteries Limited, ou=Amara Raja Batteries Limited, email=rajaram.ranganathan@amararaja.com, c=IN

M R Rajaram
Company Secretary
Encl:a/a

Vaccine juggernaut rolls into 2021, but the road abounds with bumps

Supply shortage, lack of readiness, new strain are some of the looming challenges

PT JYOTHI DATTA

Mumbai, December 31

"Vaccines offer great hope to turn the tide of the pandemic," said Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization in his new year message.

But there's also caution. The global risk of infection from SARS-CoV-2 remains, he said, until all those at risk are immunised, not just those that can afford the vaccines. And the WHO-supported COVAX facility (for equitable vaccine distribution) "urgently" needs \$4 billion, he said, to buy vaccines for low-income and lower-middle income countries.

The year 2021 will be one of "execution", where the vaccine juggernaut will truly begin to roll, to vaccinate vulnerable populations and health-workers, to start with.

But challenges loom, ranging from supply shortages to unpreparedness of hospitals to deal with possible side-effects that could arise after vaccination. And this, even as the world grapples with another variant of the virus reported in several countries, including the UK and South Africa.

The variant is seen to be more transmissible, but not

more virulent, and that could reflect on the counterintuitive ways of the virus in that it will not end the very host it needs to survive, points out Srinath Reddy, President, Public Health Foundation of India.

On the vaccines, he said it is important for people to understand that the vaccines do not prevent a person from getting the virus, but protect them from the disease (Covid-19). So, despite getting the vaccine, the person may still infect others, only maybe less, he said, reiterating that public health measures and personal protection (mask, distancing and hand-washing) must continue.

Presently, over 230 Covid-19 vaccines are in the works, 60 under clinical development and 172 in the pre-clinical stage, according to WHO. As the pandemic year ends, vaccines from the Pfizer-BioNTech combine, Moderna, AstraZeneca-Oxford University, the Gamaleya Research Institute and Sinopharm have received approvals for emergency use, either on home-turf or in other countries, as well.

India's Serum Institute has an alliance with AZ-Oxford University to make and market their vaccine in certain

Vaccines that have received 'emergency use' nod in home country or another region

Vaccine from	Platform	Doses	Indian collaboration
Pfizer-BioNTech	RNA-based	Two	Pfizer
Moderna	RNA-based	Two	None
AstraZeneca-Oxford University	Viral vector (non-replicating)	Two	Serum Institute; Wockhardt (in UK alliance with Government)
Gamaleya Research Institute (Sputnik V)	Viral vector (non-replicating)	Two	Dr Reddy's Laboratories (clinical trial); Hetero (for production)
Sinopharm	Inactivated virus	Two	None

countries. The vaccine is poised for a green signal from the Indian regulator for use in the country after it recently received an emergency use authorisation (EUA) in the United Kingdom.

Ready for side effects

Pointing to the varying efficacy levels reported on this vaccine (62 per cent, 80 per cent and 90 per cent, depending on varying and staggered doses), scientific voices call for greater transparency on vaccine trial data.

Doctors further stress the need for hospital readiness to tackle possible side effects linked to the vaccine. The AZ vaccine has had to pause global trials, for instance, to investigate a UK incident that was later cleared by the regulator. An incident reported in Chennai also was reportedly

cleared by the Indian regulator, as not linked to the vaccine.

Pfizer and Moderna have newer tech m-RNA vaccines and caution people with a history of severe allergies from taking it. Pfizer has applied for an EUA in India.

In addition to this, Russia's Sputnik V vaccine has a clinical trial alliance with Dr Reddy's Laboratories, besides a production deal with Hetero Biopharma. Other Covid-19 vaccines being developed locally include candidates from Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals, Biological E and Panacea Biotech. With this being just the local line-up, the new year will see more Covid-vaccine related activity, a development that will need an equally dynamic ecosystem to keep watch.

'Govt drove growth of EV segment'

G BALACHANDAR

Chennai, December 31

Domestic auto major Tata Motors scripted a success story in the electric car segment in Covid-19 battered 2020, which saw sales of commercial vehicles hit a decadal low due to the lockdown and resultant disruption. The company's electric SUV Nexon attracted a good number of buyers at a time the market was going through a tough phase. Shailesh Chandra, President, Passenger Vehicle Business Unit, Tata Motors, spoke to *BusinessLine* about the company's differentiated strategy, establishment of ecosystem Tata UniVerse and future plans in the electric vehicle (EV) segment. Excerpts:

How did the EV ecosystem evolve in 2020?

The fleet segment was impacted due to lower utilisation. For EVs, it's even lower because the primary use of EVs in fleet is employee transport and the primary users are e-mobility service companies such as Ola and Uber. With work from home, mobility was disrupted. People are still hesitant about travelling in Olas. However, the personal segment is doing well due to a shift towards personal mobility, and that has rubbed off on the EV industry as well. Buying a car is now at the top of the disposable income. Also, consumers are more conscious of going green.

The government has done its bit to drive faster EV adoption. How did that help?

From a government perspective,

it has taken several interventions to create an enabling environment. It is the single-most important driver, triggering the growth of the EV segment. It has done a thorough job in understanding as to how the existing barriers have to be removed to create an environment conducive for EVs from an economical point of view as well as finding ways to make it sustainable through localisation. While GST rate was cut to 5 per cent, FAME II has been possibly the best thought-through scheme across the world.

It has tried to bridge the gap between the cost of ownership of an

ICE and EV, which would have worked well had the fleet segment not been impacted. The phase-wise plan has also been really well thought through, and it is a very practical plan despite it being stretched as it allows manufacturers to localise battery packs and motors so that value addition gets done, and as the transition happens, employment remains impact. From an ecosystem perspective, it has allocated ₹1,000 crore for the charging infrastructure, which is the single big thing that needs to pick up to create an impact.

What will drive adoption of electric four-wheelers going forward?

As far as adoption is concerned, the price gap is not the major reason, because we have tested this in our Nexon. We see the potential for double-digit penetration in whichever segment we bring an EV into. The biggest change that has to come is in the



Going forward, choices, higher range and charging infrastructure will drive faster adoption of EVs

SHAILESH CHANDRA
President
Passenger Vehicle Business Unit
Tata Motors

earlier, we are also creating a portfolio of products. The ecosystem we are developing will be the single biggest factor in this approach and we are also taking localisation seriously. We have aligned our localisation to meet government requirements — the Nexon EV is the only car that meets all requirements for the FAME-II incentive, thereby making our journey more sustainable going forward. We are also the only ones who are focussing on fleet, personal and government in the EV segment.

How did your Tata UniVerse ecosystem strategy help?

We decided that in order to put an EV product on the road, we needed to provide an ecosystem supporting it. We decided to drive the growth of the ecosystem in a collaborative manner. We have partnered with Tata Power to address the challenge of charging, and both companies decided to provide a suite of charging solutions for the home, workplace, and for captive and public charging. Tata Chemicals, which is working on manufacturing lithium-ion battery cells, is exploring active chemical manufacturing and battery recycling. Tata Auto-comp is working on the localisation of battery pack assembly and motor assembly. For attractive financial solutions, we have tied up with Tata Motors Finance and Tata Capital. Further, we are exploring partnerships with some of the leading mobility service providers to open up multiple options to access Tata Motors' EV. We also use JLR's expertise in our vehicle design and have utilised the entire ecosystem a lot.

SEBI defers applicability of new NAV norms to Feb 1

OUR BUREAU

Mumbai, December 31

Capital market regulator SEBI has deferred applicability of NAV based on availability of funds for utilisation by mutual funds by a month to February due to difficulty faced by banks in providing the service to implement the new norms.

The RBI has recently streamlined opening of multiple current accounts by banks to bring in some discipline. This has posed significant unexpected challenges and has impacted banking arrangements of mutual funds, said AMFI in a statement.

Following this, AMFI had requested SEBI to defer the new norm by a month from January to prevent potential disruption of service to investors.

AMFI also wants the RBI to permit mutual funds to continue operating collection account with multiple banks to provide better service to unit holders.

Some relief

SEBI's decision to defer implementation of new norms will provide some relief to the industry as this would allow adequate time to first migrate all

banking arrangements in compliance with the RBI circular, before taking up the necessary changes in order to comply with the referred SEBI circular, said AMFI.

NS Venkatesh, Chief Executive, AMFI, said AMC's have multiple payment and collection accounts for collections, redemption, dividend, custody, intra-day, borrowing with numerous banks.

As per RBI circulars, mutual funds would need to change their operational process, restructure the banking operations at a short notice. This would involve consolidation of banking relationships and withdrawal of facilities that could potentially hamper the collection process, he said.

SIPs will be particularly impacted as investors were accustomed to getting the same day NAV allotment as most SIPs are below ₹2 lakh, he added.

SEBI has also eased trade execution and allocation norms of mutual funds. It has allowed an authorised person of the fund manager to execute the orders in equity and equity related instruments placed on the automated Order Management System.



AMARA RAJA BATTERIES LIMITED
CIN: L21402AP1985PLC003305
Registered office: Renigunta - Cuddapah Road, Karakambadi, Tirupati - 517520, Andhra Pradesh
Corporate Operations Office: Terminal A, 1-18/1/AMR/NR, Nanakramguda, Gachibowli, Hyderabad - 500032
Email: id_investorservices@amararaja.com | www.amararajabatteries.com | Tel: 91 (40) 23139000 Fax: 91 (40) 23139001

NOTICE

NOTICE is hereby given that pursuant to Regulation 47 read with 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company will be held on Saturday, February 13, 2021, inter-alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2020.

This information is available on the websites of the Company (www.amararajabatteries.com), BSE Limited (www.bseindia.com) and The National Stock Exchange of India Limited (www.nseindia.com)

For Amara Raja Batteries Limited
Hyderabad
December 31, 2020
M R Rajaram
Company Secretary

Form No. INC - 25 A
BEFORE THE REGIONAL DIRECTOR, MINISTRY OF CORPORATE AFFAIRS
SOUTH EAST REGION

In the matter of the Companies Act, 2013, section 14 of Companies Act, 2013 and rule 41 of the Companies (Incorporation) Rules, 2014

AND

In the matter of M/s AKSHRALAY ENTERPRISES LIMITED having Its Registered Office at D. No. 8-2-293/82/A/FF, 5th Floor Road no 36, Jubilee Hills Hyderabad, TG 500033 In, ...Applicant.

Notice is hereby given to the general public that the company intending to make an application to the Central Government (Regional Director, South East Region) under section 14 of the Companies Act, 2013 read with aforesaid rules and is desirous of converting into a private limited company in terms of the special resolution passed at the Annual General Meeting held on Thursday 30th, December 2020 at 11.00 A.M. at Registered office D. No. 8-2-293/82/A/FF, 5th Floor Road no 36, Jubilee Hills Hyderabad, TG 500033 In. to enable the company to give effect for such conversion to private limited company.

Any person whose interest is likely to be affected by the proposed change/status of the company may deliver or cause to be delivered or send by registered post of his objections supported by an affidavit stating the nature of his interest and grounds of opposition to Regional Director, 3rd Floor, Corporate Bhawan, GSI Post, Bandlaguda Nagole, Tattianam village, Hayat Nagar Mandal Hyderabad, Telangana 500068, Ranga Reddy (dist), within fourteen days from the date of publication of this notice with a copy to the applicant company at its registered office at the address mentioned below:

Registered office
D. No. 8-2-293/82/A/FF, 5th Floor,
Road no 36, Jubilee Hills ,
Hyderabad, TG - 500033.
Date: 31.12.2020
Place: Hyderabad

For and on behalf
AKSHRALAY ENTERPRISES LIMITED
Sd/-
Lalit Kumar Gupta
Director
(DIN: 01791575)

A SYMBOL OF PROMISE. PERFORMANCE. PERFECTION.

THE MRF TREE

MRF

The Masters of Indian Roads

2021 is a new beginning that deserves to be ushered in with a symbol of promise. A symbol that instills in every motorist, the belief that they are driving into a stellar beginning which is what the MRF Tree stands for.

As India's No.1 tyre manufacturer, we assure you, that whatever be the journey you embark upon this new year, we've got the tyres to make it a delightfully comfortable, smooth one.

MRF Limited, 114, Greaves Road, Chennai - 600 006, India. Tel: 91-44-28292777 | www.mrftyres.com
For further assistance, email us at: write2us@mrfmail.com | [f/mrfcorporate](#) | [t/MRFWorldwide](#) | [i/mrfcorporate](#)

